  | Bruyère, O., Genant, H., Kothari, M., Zaim, S., White, D., Peterfy, C., Burlet, N., Richy, F., Ethgen, D., Montague, T., Dabrowski, C., & Reginster, J.-Y. (January 2007). Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis. Osteoarthritis and Cartilage, 15 (1), 98-103. doi:10.1016/j.joca.2006.06.018  Peer Reviewed verified by ORBi |
 | Abadie, E., Ethgen, D., Avouac, B., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J.-P., Dreiser, R. L., Herrero-Beaumont, G., Kahan, A., Kreutz, G., Laslop, A., Lemmel, E. M., Nuki, G., Van de Putte, L., Vanhaelst, L., & Reginster, J.-Y. (April 2004). Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis and Cartilage, 12 (4), 263-268. doi:10.1016/j.joca.2004.01.006 Peer Reviewed verified by ORBi |
 | Zegels, B., Eastell, R., Russell, R. G., Ethgen, D., Roumagnac, I., Collette, J., & Reginster, J.-Y. (January 2001). Effect of High Doses of Oral Risedronate (20 Mg/Day) on Serum Parathyroid Hormone Levels and Urinary Collagen Cross-Link Excretion in Postmenopausal Women with Spinal Osteoporosis. BONE, 28 (1), 108-12. doi:10.1016/S8756-3282(00)00410-5 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Treves, R., Renier, J. C., Amor, B., Sany, J., Ethgen, D., Picot, C., & Franchimont, P. (May 1994). Efficacy and Tolerability of a New Formulation of Oral Tiludronate (Tablet) in the Treatment of Paget's Disease of Bone. Journal of Bone and Mineral Research, 9 (5), 615-9. doi:10.1002/jbmr.5650090505 Peer Reviewed verified by ORBi |
  | Reginster, J.-Y., Lecart, M.-P., Deroisy, R., Ethgen, D., Zegels, B., & Franchimont, P. (January 1993). Paget's Disease of Bone Treated with a Five Day Course of Oral Tiludronate. Annals of the Rheumatic Diseases, 52 (1), 54-7. doi:10.1136/ard.52.1.54 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Colson, F., Morlock, G., Combe, B., Ethgen, D., & Geusens, P. (August 1992). Evaluation of the Efficacy and Safety of Oral Tiludronate in Paget's Disease of Bone. A Double-Blind, Multiple-Dosage, Placebo-Controlled Study. Arthritis and Rheumatism, 35 (8), 967-74. doi:10.1002/art.1780350819 Peer Reviewed verified by ORBi |
 | Reginster, J.-Y., Lecart, M. P., Deroisy, R., Sarlet, N., Denis, D., Ethgen, D., Collette, J., & Franchimont, P. (1989). Prevention of Postmenopausal Bone Loss by Tiludronate. The Lancet, 2 (8678-8679, Dec 23-30), 1469-71. doi:10.1016/S0140-6736(89)92927-9 Peer Reviewed verified by ORBi |